Cushing syndrome associated with prostatic tumor adrenocorticotropic hormone (ACTH) expression after maximal androgen blockade therapy

International Journal of Urology

Volumn 14, Issue 5, 2007, Pages 436-439

  Kataoka, Kazuyoshi ^a   Akasaka, Yoshikiyo ^b   Nakajima, Kouichi ^a   Nagao, Kouichi ^a   Hara, Hiroshi ^a   Miura, Kazukiyo ^a   Ishii, Nobuhisa ^a  

^a TOHO UNIVERSITY   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adrenocorticotropic hormone (ACTH); Cushing syndrome; Neuroendocrine cell; Prostate cancer

Indexed keywords

BICALUTAMIDE; CORTICOTROPIN; HYDROCORTISONE; LEUPRORELIN; METYRAPONE; POTASSIUM; PROSTATE SPECIFIC ANTIGEN; STEROID;

AGED; ARTICLE; ASPIRATION BIOPSY; AUTOPSY; BIOPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; DEATH; DIGITAL RECTAL EXAMINATION; DRUG PULSE THERAPY; DYSPNEA; ECTOPIC CORTICOTROPIN PRODUCTION; HEMATURIA; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INFLAMMATION; LABORATORY TEST; LEG EDEMA; LUNG LOBE; MALE; METASTASIS; NOCTURIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RESPIRATORY FAILURE; SUPPLEMENTATION; THORAX;

ADRENOCORTICOTROPIC HORMONE; AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; CUSHING SYNDROME; HUMANS; LEUPROLIDE; MALE; NITRILES; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 34248657567     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01710.x     Document Type: Article

References (10)

1. Azzopardi JG, Evans DJ. Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J. Pathol. 1971 104 : 247 52.
2. Hagood PG, Johnson FE, Bedrossian CW, Silverberg AB. Small cell carcinoma of the prostate. Cancer 1991 67 : 1046 50.
3. Capella C, Usellini L, Buffa R, Frigerio B, Solcia E. The endocrine component of prostatic carcinomas, mixed adenocarcinoma-carcinoid tumors and non-tumor prostate: histochemical and ultrastructural identification of the endocrine cells. Histopathology 1981 5 : 175 92.
4. Abrahamsson PA, Falkmer S, Fält K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas: an immunohistochemical study testing chromogranin A as an 'endocrine marker'. Pathol. Res. Pract. 1989 185 : 373 80.
5. White A, Gibson S. ACTH precursor: biological significance and clinical relevance. Clin. Endocrinol. 1988 48 : 251 5.
6. Rickman T, Garmany R, Doherty T, Benson D, Okusa MD. Hypokalemia, metabolic alkalosis, and hypertension: Cushing syndrome in a patient with metastatic prostate adenocarcinoma. Am. J. Kidney Dis. 2001 37 : 838 46.
7. Hussein WI, Kowalyk S, Hoogwerf BJ. Ectopic adrenocorticotropic hormone syndrome caused by metastatic carcinoma of the prostate: therapeutic response to Ketoconazole. Endocr. Pract. 2002 8 : 381 4.
8. Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer 2002 95 : 1415 20.
9. Moore SR, Reinberg Y, Zhang G. Small cell carcinoma of the prostate: effectiveness of hormonal versus chemotherapy. Urology 1992 39 : 411 16.
10. Susan SF. Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing? Nat. Clin. Pract. 2006 3 : 138 44.